Short answer
ACCENDRA HEALTH INC/VA/ (ACH) filed its Q3 2026 10-Q quarterly report on Nov 6, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $602M (down 13.7% year over year) with net income of −$20M.
Q3 2026 key financials · XBRL
- Revenue
- $602M
- −13.7% YoY · −1.9% QoQ
- Net income
- −$20M
- +86.9% YoY · +77.9% QoQ
- Operating margin
- 0.2%
- EPS (diluted)
- −$0.25
- +87.2% YoY · +78.6% QoQ
Source: XBRL data from the ACCENDRA HEALTH INC/VA/ (ACH) Q3 2026 10-Q on SEC EDGAR. USD.
ACCENDRA HEALTH INC/VA/ Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Net revenue $601.8M, down 13.7% YoY from $697.3M, driven by commercial Payor contract termination
- Cost margin 43.4% vs 46.2% YoY, with cost of net revenue 56.6% vs 53.8%
- Best segment: Ostomy revenue $55.2M, up 3.7%; worst: Sleep therapy $144.5M, down 22.2%
- Cash $26.6M vs $282.0M at December 31, 2025; operating cash flow $(93.5)M
- Free cash flow $(5.8)M vs $29.2M YoY; management cites value creation plan and continued sleep and respiratory growth needs
Risk Factors
- NYSE price compliance risk: October 6, 2026 notice after 30-day average below $1, requiring cure within six months
- NYSE capitalization compliance risk: October 27, 2026 notice for market capitalization and equity below $50 million
- Delisting risk: reverse split proposal, targeted at 1-for-20 to 1-for-30, requires shareholder approval
- Management transition risk: executive departures could cause operational inefficiencies and increased turnover
- No other material changes through September 30, 2026 beyond identified NYSE and leadership risks
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ACCENDRA HEALTH INC/VA/ quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.